Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Nano-X Imaging Ltd.    NNOX   IL0011681371


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Kirby McInerney LLP Announces the Filing of a Securities Class Action Lawsuit Against Nano-X Imaging Ltd.

share with twitter share with LinkedIn share with facebook
09/18/2020 | 04:51pm EDT

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of New York on behalf of those who acquired Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX) securities during the period from August 21, 2020 through September 15, 2020 (the “Class Period”). Investors have until November 16, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Nano-X’s commercial agreements and its customers were fabricated; (2) Nano-X’s statements regarding its “novel” Nano-X System were misleading as the Company never provided data comparing its images with images from competitors’ machines; (3) Nano-X’s submission to the U.S. Food and Drug Administration (“FDA”) admitted the Nano-X System was not original; and (4) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you acquired Nano-X securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney at 212-371-6600, by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney’s website: www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

© Business Wire 2020

share with twitter share with LinkedIn share with facebook
All news about NANO-X IMAGING LTD.
10/29NANO X IMAGING : Nanox Signs With Ambra Health to Enable Image Access and Transf..
10/29Nanox Signs With Ambra Health to Enable Image Access and Transfer with U.S. H..
10/28NANO X IMAGING : ROSEN, A TOP RANKED LAW FIRM, Reminds Nano-X Imaging Ltd. Inves..
10/27ROBBINS GELLER RUDMAN & DOWD LLP : Announces Lead Plaintiff Deadline in the Nano..
10/26NANO X IMAGING : Nanox to Announce Third Quarter 2020 Financial and Operating Re..
10/26Nanox to Announce Third Quarter 2020 Financial and Operating Results on Monda..
10/22NANO X IMAGING : The Law Offices of Frank R. Cruz Announces the Filing of a Secu..
10/20NNOX INVESTOR ALERT : Bernstein Liebhard Reminds Investors of the Deadline to Fi..
10/18NANO X IMAGING : ROSEN, A TOP RANKED LAW FIRM, Reminds Nano-X Imaging Ltd. Inves..
10/17SHAREHOLDER ALERT : Pomerantz Law Firm Reminds Shareholders with Losses on their..
More news
Financials (USD)
Sales 2020 0,83 M - -
Net income 2020 -30,0 M - -
Net cash 2020 232 M - -
P/E ratio 2020 -37,6x
Yield 2020 -
Capitalization 1 345 M 1 345 M -
EV / Sales 2020 1 336x
EV / Sales 2021 55,0x
Nbr of Employees 27
Free-Float 72,4%
Duration : Period :
Nano-X Imaging Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NANO-X IMAGING LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Average target price 67,50 $
Last Close Price 29,16 $
Spread / Highest target 140%
Spread / Average Target 131%
Spread / Lowest Target 123%
EPS Revisions
Ran Poliakine Chairman & Chief Executive Officer
Itzhak Maayan Chief Financial Officer
Yoel Raab Chief Technology Officer
Amir Ben-Shalom Chief Scientific Officer
Onn Fenig Director
Sector and Competitors